introduction covid-19 pandemic declared march following first case sars-cov-2 coronavirus pneumonia reported wuhan china december frequent clinical manifestation fever cough dyspnoea may complicated acute respiratory distress syndrome multi-organ failure death however digestive symptom diarrhoea vomiting abdominal pain described patient infectious disease represents key challenge gastroenterologist patient inflammatory bowel disease ibd potential risk group required special attention pandemic given altered immune response play key role pathogenesis ibd vast majority drug used modulate immune system function ibd patient considered high risk sars-cov-2 infection severe disease however current data appear demonstrate increased risk infection severity patient ibd relative general population except corticosteroid therapy even patient present mild course infection low incidence hospital admission low fatality rate active disease age comorbidities risk factor covid-19 mortality patient ibd ioibd supervision international registry secure-ibd created tracking reported case since march october 6,635 case reported required artificial ventilation death patient ibd association covid-19 disease immunologically spike protein key immune target coronavirus infection protein closely associated production neutralizing antibody protective immunity protein responsible interaction sars-cov-2 host cell ace2 binding divided two region region contains second domain receptor binding domain rbd make serological testing useful tool identifying patient contracted infection figueiredo-campos demonstrated antibody sars-cov-2 protein rbd domain easily detectable case even patient receiving immunosuppressant antiretroviral therapy classical immune response antibody sars-cov-2 blood reach peak around week three post-infection although antibody level reduced igg antibody remain detectable show neutralising activity least month infection known serological response vaccination may lower immunocompromised patient specific case ibd several study shown response hepatitis anti-pneumococcal vaccination lower patient treated immunosuppressant and/or biological therapy aim study define patient ibd seroprevalence igg-sars-cov-2 one year beginning pandemic area high risk infection madrid spain seroconversion patient known covid-19 infection relationship drug used treatment ibd material method single-centre descriptive study cohort patient pre-exisiting diagnosis ibd recruited february march one year start pandemic country first case madrid spain diagnosed february patient ibd follow-up unit scheduled on-site visit included patient received dose covid-19 vaccine included patient included completed detailed questionnaire symptom indicative sars-cov-2 infection demographic data clinical information ibd appendix definition case used reference evaluates result pcr antigen determination symptomatology define confirmed probable suspected case confirmed case person tested positive nucleic acid amplification test naat person tested positive rapid antigen detection test sars-cov meet clinical radiological criterion probable suspected case asymptomatic person tested positive rapid antigen detection test contact probable confirmed case included patient underwent qualitative serology two chemiluminescent immunoassay clia technique siemens atellica detects total antibody vircell virclia detects igg siemens cut-off point one value considered positive negative virclia 1.4 negative 1.4 1.6 doubtful result 1.6 positive siemens test positive considered igg positive siemens result low positive negative virclia test performed determination coincided given igg positive negative result coincide result indeterminate decided perform different determination previously checked microbiology department due disparity finding reflected study ethical consideration study evaluated ethic committee paz university hospital madrid code pi-4637 patient included signed informed consent form order participate study study protocol conforms ethical guideline declaration helsinki statistical analysis since descriptive study doe include contrast hypothesis prior calculation sample size necessary descriptive analysis baseline ibd-related characteristic performed continuous variable mean standard deviation calculated categorical variable percentage confidence interval calculated provided variable normal distribution verified shapiro wilk test categorical variable compared using test quantitative variable compared using student t-test otherwise corresponding non-parametric test applied value 0.05 considered statistically significant result total patient included baseline characteristic summarized table related ibd table patient previously excluded already received dose covid-19 vaccine table baseline characteristic full size table table ibd characteristic full size table average age patient included time analysis 49.23 year 15.4 regarding treatment followed patient time start pandemic march monotherapy biologics frequent patient 26.99 followed patient combined treatment biologic immunosuppressant patient 15.42 immunosuppressant monotherapy patient 14.65 patient treatment drug regarding type biologic used patient patient infliximab patient adalimumab patient vedolizumab 13.2 patient ustekinumab time analysis july percentage patient biologics increased compared beginning pandemic therapy alone combination immunosuppressant patient immunomodulatory therapy alone decreased 12.1 patient finally patient 2.3 corticosteroid treatment distribution term use different biological drug differ significantly shown march respect serology extracted ass seroprevalence igg antibody sars-cov-2 patient ibd patient 73.15 negative patient 17.65 positive patient 9.21 result indeterminate among included patient patient previous probable confirmed sars-cov-2 infection patient 66.7 positive pcr 27.8 patient previous documented positive serology igg sars-cov-2 frequent symptom among patient infection fever 61.4 general malaise 70.5 headache 64.1 duration symptom averaged 17.04 day 21.16 experience 19.23 sample patient required hospital admission due covid-19 among patient admitted presented comorbidities however sample comorbidity hbp obesity cardiovascular disease copd asthma chronic renal disease personal history cancer etc 35.7 admitted hospital 0.09 logistic regression analysis hbp 2.99 ic95 0,3–21,9 obesity 4.15 ic95 0,5–43,1 shown significant furthermore found percentage patient requiring hospitalisation differed treatment biological and/or immunosuppressant drug others without therapy 0.16 admission biological therapy possibility developing igg antibody sars-cov-2 patient previous positive pcr analysed among patient documented positive pcr patient 65.4 positive antibody 15.3 indeterminate igg titre 0.53 time positive pcr sars-cov-2 antibody test day median iqr 85–329 obtained similar data investigating probability developing antibody patient criterion past infection although necessarily positive pcr test patient positive antibody patient 12.5 indeterminate compared patient positive antibody among 5.2 history covid-19 infection 0.0001 one important issue analyse rate seroconversion patient biologics immunosuppressant seroconversion analysed among patient biological treatment patient previous positive pcr developed antibody 56.5 case result indeterminate 17.4 however analysed influence immunosuppressant treatment probability developing antibody among patient previous positive pcr test identified similar without treatment 77.8 77.1 0.96 analysed influence biological treatment anti-tnf possibility developing antibody finding among patient positive pcr test 54.5 6/11 patient developed antibody using anti-tnf drug compared 20/33 patient among treatment 0.03 furthermore compared influence different type biologic according therapeutic target identified overall 38.9 7/84 patient patient anti-tnf positive antibody compared 61.1 11/37 patient among ustekinumab vedolizumab 0.002 fig figure percentage antibody-positive patient anti-tnf vedolizumab/ustekinumab therapy full size image similarly analysed seroconversion rate among patient previous positive pcr test found 54.5 6/11 patient anti-tnf group versus 85.1 6/7 patient vedolizumab ustekinumab group 0.17 finally find baseline characteristic sex patient age type ibd included patient statistically significantly associated antibody formation however analysed influence patient work situation pandemic found in-person semi in-person job 24.1 35/145 patient positive antibody compared 34/210 patient need workplace either working remotely retired unemployed 0.05 noted patient associated comorbidity patient 18.6 developed antibody compared without presence comorbidity 0.045 discussion cohort patient 17.65 patient showed igg-sars-cov-2 one year onset pandemic spain ministry health conducted population-based seroprevalence study using rapid antibody test estimated positivity rate 11.7 10.3–13.3 madrid june difference may due different type assay used difference time performance consistent seroprevalence madrid higher significantly higher geographical area spain important note patient included study biological/immunosuppressant treatment furthermore observed routine clinical practice following recommendation different scientific society suspend immunosuppressant biological therapy generalised manner fact number patient treated biologics increased avoiding use corticosteroid drug associated greater severity disease one relevant data study patient data probable previously confirmed infection antibody time study figure much lower reported general population exceeds seroconversion however given cross-sectional nature study data may due loss antibody month infection due lack antibody development patient population percentage even lower patient treated biologics although compared percentage patient exposed treatment statistical significance reached antibody concentration shown remain attenuated patient treated infliximab patient reinfection frequent occurred earlier patient treatment analysing seroconversion data relation biological drug used patient relevant point patient anti-tnf treatment lower percentage positive serology compared biologics ustekinumab vedolizumab fact maintained among known previous infection finding consistent published work finally found influence variable type disease sex age presence antibody find possible greater exposure continued attend place work person compared remained home limitation study include fact first wave pandemic march may emergency health situation meant case microbiological confirmation diagnosis made solely basis clinical/radiological criterion following definition moreover since cross-sectional study difficult differentiate patient past sars-cov-2 infection develop antibody developed antibody primary infection subsequently lost conclusion seroprevalence antibody sars-cov-2 17.65 one year beginning pandemic region high prevalence infection cohort presence antibody likely among treated anti-tnf biologics overall seroconversion known infection general population finding may impact future protective measure vaccination patient population datasets generated and/or analysed current study available corresponding author reasonable request